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Abstract
Retinitis Pigmentosa, most commonly characterized by night blindness and loss of peripheral vision, is a rare genetically inherited 
group of diseases affecting the retina of the eye . It is estimated that 1 in 4000 people in the USA are affected by some form of the 
disease . Retinitis Pigmentosa (RP), is caused by a mutation or change in one or more of 55 genes . There are many causes to this 
disease as RP presents with many different symptoms and biological effects on the eye .  These are then grouped together because 
they share a common result, deterioration of vision . Presently, there is no cure for the disease . Most of the present therapies are 
aimed at preserving visual function and preventing or slowing further cell death. Restoring vision is particularly difficult because 
human photoreceptors are not produced and do not divide after birth and therefore their loss is irreversible . Experimentation in 
gene and stem cell transplantation to retard the advance of the disease, as well as drug therapies and surgeries to diminish the 
effects of the disease are ongoing and have found some limited success .
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Introduction
The eyeball consists of three main layers and is one of the most 
complex organs in the body (fig.1). The outermost layer, the 
fibrous tunic, is made up of the sclera and the cornea. Then the 
middle layer, the vascular layer, consists of the ciliary body, iris 
and choroid. The innermost layer is the nervous tunic which 
consists of the retina. The retina contains two types of photo-
receptor cells, the rods and cones. The rods and cones absorb 
and convert light into electrical signals that are then sent to 
the brain. The rod and cone cells are present throughout the 
retina with the exception of the fovea, the center of the retina, 
where only cone cells are present. Rod cells are accountable for 
peripheral and night vision whereas cone cells are accountable 
for more direct visual functions like reading, driving and facial 
recognition. The rods allow us to see in dim light and the cones 
allow us to see color and details.
RP can manifest itself as early as the first years of life, 
childhood, adolescence or young adulthood.  Near the begin-
ning stage it is hard to detect the disease, especially if there 
is no familial history, as most daily functions are not affected. 
The slow regressive pattern of deterioration that defines RP 
presents in the onset of the disease with night blindness and the 
reduction of peripheral vision. The lack of peripheral vision in 
the day becomes apparent when incidents like not seeing pedes-
trians walking, not noticing cars approaching from the side while 
driving, or missing handshakes when greeting people occur. As 
the disease advances patients become sensitive to light. This 
often leads to reading difficulties and difficulty perceiving pale 
colors particularly in the blue and yellow tones.
In the last stages as the cones begin to be more affected the 
vision field continues to narrow, and the light sensitivity contin-
ues to grow. Often patients are still able to read a little, usually 
with a magnifying glass, until the central visual field vanishes. 
Usually patients can still perceive light.
Methods
Articles and studies researched in this paper were obtained 
through the EBSCO and ProQuest databases with access pro-
vided by the Touro College Library. Images and diagrams that 
are used throughout the paper were obtained from the re-
search articles cited.
How is RP Inherited?
RP is a progressive inherited disease that occurs in one of three 
ways: autosomal recessive inheritance, autosomal dominant in-
heritance, or X-linked inheritance. Autosomal recessive inheri-
tance happens when both the mother and father are carriers 
of the recessive gene mutation giving them a 1 in 4 chances of 
having a child with the disorder. The parents typically do not 
show any signs or symptoms of the disease. Autosomal domi-
nant inheritance happens when one parent has a dominant gene 
mutation giving them a 1 in 2 chance of having a child with the 
disorder. In this form of the disease there is often a parent and 
other members of the family with the disease.
X-linked inheritance is when the mutated gene is on one of 
the X-chromosomes. It can be passed on to sons who inherit 
only one X-chromosome and cannot offset the gene with their 
Y- chromosome. Sons from mothers that are X-linked carriers 
Fig 1
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have a 1 in 2 chances of having the disease. Fathers with X-linked 
RP cannot pass the disease on to their sons. Girls inheriting only 
1 affected X-chromosome have a 1 in 2 chance of being carriers. 
Girls usually need both X-chromosomes affected to get the dis-
ease. There are a small minority of woman who get the disease 
with only one X-chromosome affected. X-linked inheritance is 
by and large thought to be the most severe form of RP and can 
begin in early childhood (Melamud, 2006).
In a situation where only one person in the family is affected, 
the disease is referred to as simplex. These cases could be the 
result of small families where there are few possible relatives 
to be affected, or it could be the result of a new gene mutation. 
RP is primarily a monogenic inherited disease. This form of 
inheritance refers to a single gene controlling a genetic trait. 
Digenic inheritance refers to a disease that is inherited through 
the mutation of two interacting genes. There are many diseases 
caused by single gene mutations but so far very few have been 
found which are caused by mutations in at least one copy of 
two genes interacting. Digenic inheritance is a rare form of the 
genetically complex RP.
How are the Rods and Cones Damaged?
RP is caused by the loss of use of the rods and cones. It is typ-
ified by the initial loss of rod function followed by the death of 
the cones. It is the genetic mutation that causes the initial rod 
death, but the subsequent cone death is thought to be caused 
by its dependence on the rods. It is the loss of the cones that 
causes the severe blindness associated with the disease.
The rhodopsin genes’ function is to encode a protein called 
rhodopsin in the rod cells. Rhodopsin absorbs the light that 
is then converted into electrical signals in the rods. The most 
common cause of autosomal dominant RP is a sequence varia-
tion in the rhodopsin gene (Schuster, 2005).
Mutations in the rhodopsin genes obstruct their ability to 
function properly and are the cause of over 25%, of autoso-
mal-dominant RP cases. The alteration at a specific point ac-
counts for the difference in the disease expression within fami-
lies. The majority of the mutations affect the folding, and stability 
of the rhodopsin molecule (Terray, et. al. 2017). In other forms 
of the disease the mutations produce a protein that is toxic 
to the cell, or the mutation doesn’t allow the cell to function 
properly. As a result, the rods followed by the cones cease to 
function and slow progressive vision loss occurs (Jensen, 2016).
Discussion
While there is a great deal of re search on the genetic sources 
of the disease, there is still much to be discovered and studied 
to extend our knowledge and treat RP effectively. For example, 
most of the current research focuses on the etiology of RP. 
However, because of the many differing genetic mutations that 
cause RP there is very little research that can be done on the 
disease as a whole, but it is rather approached in a very specific 
type by type manner. Since most of the accepted approaches 
target specific versions of the disease, they are only beneficial 
to particular groups of patients. 
In the past few years there has been a vast amount of sci-
entific research into treatments for RP. These include surgical, 
pharmacological and non-invasive treatments. 
Recent studies have shown that as the rods degenerate, the 
cones are deprived of glucose and eventually die. The photore-
ceptors are dependent on glucose in order to function properly. 
One of the symptoms of RP is the breakdown of this process.
Muller cells, which are non-neural cells of the retina, serve to 
protect the retina by providing a conduit to transport glucose 
to the photoreceptors, remove debris and provide electrical 
and mechanical support of the neural retina. The Muller cells 
are among the first to show signs of metabolic changes in the 
retinal degeneration of RP and are among the last cells left in 
the degenerate retina. As RP progresses, the Muller cells follow 
a chaotic metabolic path. Unlike the precise cohesive response 
Muller cells exhibit in healthy retinas, they appear to react to 
the degenerating photoreceptors in an unfamiliar non-homoge-
neous manner. The remodeling of the retinal cells caused by cell 
stress and death is an unavoidable consequence of the progres-
sion of the disease (Pfeiffer, et. al. 2016).
As the photoreceptors degenerate, the surviving rods and 
cones reorganize (fig. 2). This is followed by the adjustment of 
inner retinal components such as the neurons, the glial cells 
and the blood vessels. This process of remodeling cannot be 
explained as an attempt to produce new cells as retinal cells 
cannot be reproduced or regrown. It is rather seen as a reaction 
to one or more possible negative inputs that causes the remod-
eling and the eventual cell death. The course of the photorecep-
tor cell death is dependent of the underlying genetic mutation, 
the type of RP. The path of the inner retinal layer degeneration is 
Fig . 2 Normal retina vs . reorganization of the retina in a patient with 
RP (Rawa .com) 
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similar in spite of the differing underlying genetic mutation. This 
is significant in the search for a cure or a reversal of at least part 
of the progressive path of the disease.
The complex biological process of retinal remodeling is an 
active field of retinal investigation, as it shows promise for ther-
apeutic treatments of the disease (Terray, et. al. 2017). 
Scientists have tried a number of ways to surgically reverse 
this process. One of the methods is that they have attempt-
ed to bypass the effective rods by surgically replacing them 
and restoring the transportation of glucose to the cones. The 
cones remain latent for a period of time before they die and 
if the glucose supply can be replenished before that time they 
can be regenerated. In a study of rod transplantation, the rods 
from healthy mice were transplanted into RP affected mice that 
were totally lacking rods but still had some functioning cones. 
These mice were compared to a control group of RP mice to 
measure the normal degeneration for the same period of time. 
Two weeks after surgery the number of functioning cones were 
compared between the two groups of mice. Those mice that 
received transplanted healthy rods showed 40% greater cone 
survival than untreated mice. Another surgical method that has 
shown potential as a treatment for RP is the placement of glu-
cose directly under the retina so as to regenerate and reactivate 
the cones (Mohand-Said, 2000).
The objective of the rod transplantation surgery is to help 
the survival of the cones as they gradually deteriorate over 
time and ultimately to prevent blindness from occurring. This 
is different than other surgical treatments being tried, such as 
cataract surgery. In cataract surgery the lens of the eye is re-
moved and replaced because the lens has become cloudy and 
thus the person’s vision is cloudy. For RP patients with progres-
sively limiting vision the start of cataracts can advance the loss 
of vision significantly. Therefore, cataract surgery has been found 
to be beneficial in some cases of RP. The difference between 
the rod replacement surgery attempts and cataract surgery is 
their goals. While they both are trying to restore as much sight 
as possible, the rod replacement surgery is trying stop the pro-
gression of the disease by replacing the genetically affected rods. 
By contrast the cataract surgery is treating only the symptoms 
and not the underlying cause (Dikopf, et. al. 2013).
There are also a vast number of non-surgical research studies 
being done. One of the first symptoms of RP is night blindness 
and difficulties with dark adaptation. Researchers have investi-
gated the use of antipsychotic drugs on RP given that the side 
effect of certain specific drugs of this type is increased light sen-
sitivity. The increase in light sensitivity produced by these drugs 
was compared to their known adverse side effects to determine 
if they could be a useful treatment in RP.
Most antipsychotic drugs act as dopamine antagonists. They 
block the dopamine receptors. In order to reach the photore-
ceptors, incoming light must first pass through all the cell layers 
of the retina. The first layer is composed of the ganglion cells. The 
ganglion cells are a type of neuron in the inner surface of the ret-
ina that transmit information to the brain. Between the photore-
ceptor and the ganglion cells there are bipolar cells that transmit 
signals from the photoreceptor to the ganglion cell. The ganglion 
cell receptive fields are subdivided into two parts, center and sur-
round. They operate in an ON center OFF surround or an OFF 
center ON surround manner. In the ON center/OFF surround a 
small ray of light in the center increases the cells response. An Off 
center On surround has the opposite effect where a small ray of 
light in the center inhibits the cells response.
The antipsychotic drugs haloperidol and clozapine were test-
ed to see whether they could similarly alter the light responses 
of the retinal ganglion cells (RGCs) in the rat retinas.
The drugs have the effect of transforming abnormal long la-
tent ON-center RGCs into Off-center cells. It is believed that 
these RGCs might have been Off-center cells early in the onset 
of the disease. Antipsychotic drugs are divided into two cate-
gories, typical and atypical. The difference between these two 
categories is the side effects they produce. Atypical antipsychot-
ic drugs like clozapine are considered second generation anti-
psychotic drugs that have fewer negative side effects than the 
first-generation drugs like haloperidol. The responses of the ret-
inas of the rats were recorded before and after the application 
of the various drugs. Both haloperidol and clozapine increased 
light sensitivity of the affected rat retinas. For those retinas 
that exhibited an abnormally long latency ON response to the 
onset of a small spot of light, both haloperidol and clozapine 
brought about a change and a reduction in the long latency ON 
response. Both these drugs act as an antagonist to receptors in 
the rats. The haloperidol acts as a D2 receptor antagonist while 
the clozapine acts on the D2 receptor as well as a 5-HT2A 
(serotonin) receptor antagonist. On the whole, the results imply 
that antipsychotic drugs may be useful in temporarily improving 
vision in patients with RP (Jensen, 2016).
Other pharmacological treatments such as the supplementa-
tion of different vitamins, DHA (docosahexaenoic acid) a type 
of omega 3 fatty acid, oral valproic acid and topical brimonidine 
tartrate NGF drops, are all being explored in the hope they can 
help of protect and slow the progression of the disease.
Vitamin A is a powerful antioxidant that has been found to 
be essential for good vision, eye health and the ability to help 
protect the eyes from night blindness and age-related degenera-
tion. Supplementation of vitamin A over a period of 4 to 6 years 
showed a significantly slower rate of visual decline. The study 
included different genetic types of RP as well as children in the 
early stages of the disease. These results contrasted the results 
of the supplementation of vitamin E. Patients receiving vitamin 
E showed a greater loss of retinal function than placebo groups.
In a 4-year study of DHA supplementation vs. placebo the 
loss rate of cone and rod function was not appreciably different. 
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Another study comparing the effects of taking DHA with vita-
min A or taking vitamin with a placebo showed that the addition 
of the DHA did not alter the results of the effects of the vitamin 
A on RP patients. The rate of decline of the progression of the 
disease remained the same (Sacchetti, 2015).
Nerve Growth Factor
NGF, nerve growth factor, is important in the regulation, growth 
and survival of the neurons. It has been found to promote the re-
covery of neuronal damage in several animals. NGF drops were 
administered in a 10-day trail to see the short-term effect of the 
drops on patients with advanced stages of RP.  The possible adverse 
effect of the drops was monitored closely. The study showed nei-
ther adverse effects nor significant improvement in RP patients.
Stem Cell
Stem cell transplantation is a potential treatment that is show-
ing great promise.  Allogeneic stem cell transplantation, which 
are stem cells taken from matching donors, or human embry-
os, have the potential to be effective and safe. However, there 
is the ongoing controversial debate on the morality of using 
embryonic tissue in medical experiments or treatments. This 
issue coupled with the greater risk of rejection and need for 
immunosuppressant therapy when using allogeneic stem cells 
has encouraged scientists to investigate the use of autologous 
stem cells transplantations, which are treatments using stem 
cells derived from the patients themselves (Bassuk, et. al. 2016).
IPS: Induced Pluripotent Stem Cells
IPS cells, induced pluripotent stem cells are autologous stems 
cells that come from the person’s own skin or blood cells. These 
cells are then reprogrammed to enable them to develop into 
any type of human cell.
The use of IPS cells as a treatment for RP has shown some 
promise in restoring some of the lost vision. Because of the 
many different genetic causes of RP there is hope of developing 
specific IPS cells to target precisely the various forms of the 
disease independently. The goal of this treatment is to edit and 
correct the patient’s pathogenic mutation in very specific type 
by type RP cases. X-linked RP is a very aggressive form of the 
disease. IPS cells have been used in studies to try to correct 
the specific X-linked form of the disease and have been found 
to correct 13% of the gene mutation that causes the X-linked 
RP. Researchers are optimistic with their success of the gene 
editing treatment of X-linked RP thus far. It establishes that this 
treatment should be continued to be studied and used as part 
of autologous transplantation of other photoreceptor degen-
eration cases.
There are still other challenges with this treatment due to 
complications with incorrect placement, the development of 
tumors and disturbance of other types of cell which need to be 
resolved in order to further the use of this stem cells research 
(Bassuk, et.al. 2016).
In contrast to the pharmaceutical approach to the early onset 
of light sensitivity and vision loss, the nonpharmacological inter-
ventions are based on strategies of light protection. The use of 
specialized electronic glasses to protect the eye from contact 
with light has been employed. In more advanced stages of RP 
there is the Argus ll which combines both glasses with surgery. 
The Argus ll involves the implantation of an artificial device that 
must connect to a functioning optic nerve. Electrodes are then 
implanted into the eye and connected to the glasses that can 
convert images into electrical pulses that the brain perceives as 
patterns of light.
Conclusion
There is promising research for treating the symptoms of RP. 
There is also promising research into fixing the underlying ge-
netic mutation that is associated with RP, with the use of stem 
cell therapy. Continued research is needed before the stem cell 
therapy can be used as a widespread treatment. it is the goal of 
researchers to treat patients earlier on in the progression of the 
disease, before complete visual function is lost.
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